Mesoblast Total Operating Expenses vs Selling And Marketing Expenses Analysis

MESO Stock

USD 11.69 0.11 0.95%

Mesoblast financial indicator trend analysis is infinitely more than just investigating Mesoblast recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Mesoblast is a good investment. Please check the relationship between Mesoblast Total Operating Expenses and its Selling And Marketing Expenses accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mesoblast. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.

Total Operating Expenses vs Selling And Marketing Expenses

Total Operating Expenses vs Selling And Marketing Expenses Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Mesoblast Total Operating Expenses account and Selling And Marketing Expenses. At this time, the significance of the direction appears to have very week relationship.

The correlation between Mesoblast's Total Operating Expenses and Selling And Marketing Expenses is 0.25. Overlapping area represents the amount of variation of Total Operating Expenses that can explain the historical movement of Selling And Marketing Expenses in the same time period over historical financial statements of Mesoblast, assuming nothing else is changed. The correlation between historical values of Mesoblast's Total Operating Expenses and Selling And Marketing Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Operating Expenses of Mesoblast are associated (or correlated) with its Selling And Marketing Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Selling And Marketing Expenses has no effect on the direction of Total Operating Expenses i.e., Mesoblast's Total Operating Expenses and Selling And Marketing Expenses go up and down completely randomly.

Correlation Coefficient

0.25

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Selling And Marketing Expenses

Most indicators from Mesoblast's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Mesoblast current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mesoblast. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.As of the 1st of December 2024, Enterprise Value is likely to grow to about 1.2 B, while Selling General Administrative is likely to drop about 20.5 M.

	2021	2022	2023	2024 (projected)
Interest Income	3K	831K	1.8M	1.9M
Reconciled Depreciation	4.4M	4.1M	4.7M	4.0M

Interest Income Reconciled Depreciation

Mesoblast fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Intangible Assets	Current Deferred Revenue	Good Will	Non Current Liabilities Total	Short Term Debt	Non Currrent Assets Other	Common Stock Total Equity	Inventory
Total Assets		0.0	0.55	0.95	0.34	-0.1	-0.07	0.74	0.06	0.94	0.06	0.08	0.38	0.32	0.1	0.88	0.01	0.64	0.94	-0.18	0.6	0.26	0.27	-0.03	0.01	-0.14
Other Current Liab	0.0		0.45	0.04	0.22	0.43	-0.72	-0.35	0.17	0.03	0.17	0.19	0.26	-0.01	0.16	-0.08	0.6	-0.09	0.01	-0.57	0.38	-0.41	-0.08	-0.19	0.59	-0.46
Total Current Liabilities	0.55	0.45		0.58	0.78	-0.02	-0.46	0.35	0.48	0.54	0.48	-0.18	0.46	0.22	0.61	0.4	0.33	0.31	0.51	-0.42	0.42	-0.23	0.19	-0.57	0.56	-0.37
Total Stockholder Equity	0.95	0.04	0.58		0.4	-0.03	-0.18	0.73	0.1	0.92	0.1	0.15	0.52	0.36	0.18	0.7	0.06	0.57	0.91	-0.23	0.5	-0.02	0.37	-0.14	0.16	-0.31
Property Plant And Equipment Net	0.34	0.22	0.78	0.4		0.11	-0.5	0.44	0.37	0.38	0.37	-0.3	0.59	0.12	0.68	0.19	0.53	0.09	0.35	-0.55	0.25	-0.27	0.15	-0.7	0.58	-0.41
Net Debt	-0.1	0.43	-0.02	-0.03	0.11		-0.64	-0.08	-0.6	0.05	-0.6	0.23	0.27	0.29	-0.07	-0.19	0.54	-0.38	0.04	-0.61	0.38	-0.23	-0.03	-0.12	0.52	-0.56
Retained Earnings	-0.07	-0.72	-0.46	-0.18	-0.5	-0.64		0.07	-0.16	-0.25	-0.16	-0.17	-0.61	-0.19	-0.28	0.12	-0.87	0.36	-0.22	0.81	-0.44	0.58	-0.06	0.35	-0.92	0.82
Accounts Payable	0.74	-0.35	0.35	0.73	0.44	-0.08	0.07		-0.13	0.79	-0.13	-0.18	0.31	0.37	0.15	0.62	-0.1	0.27	0.79	0.05	0.49	0.23	0.55	-0.15	-0.06	-0.22
Cash	0.06	0.17	0.48	0.1	0.37	-0.6	-0.16	-0.13		0.01	1.0	-0.06	0.17	-0.07	0.53	-0.03	0.15	0.12	-0.01	0.01	-0.24	-0.36	-0.05	-0.37	0.27	-0.06
Non Current Assets Total	0.94	0.03	0.54	0.92	0.38	0.05	-0.25	0.79	0.01		0.01	0.08	0.49	0.43	0.15	0.79	0.11	0.34	1.0	-0.22	0.72	0.14	0.41	-0.11	0.19	-0.41
Cash And Short Term Investments	0.06	0.17	0.48	0.1	0.37	-0.6	-0.16	-0.13	1.0	0.01		-0.06	0.17	-0.07	0.53	-0.03	0.15	0.12	-0.01	0.01	-0.24	-0.36	-0.05	-0.37	0.27	-0.06
Net Receivables	0.08	0.19	-0.18	0.15	-0.3	0.23	-0.17	-0.18	-0.06	0.08	-0.06		0.25	0.39	-0.33	-0.04	0.04	0.06	0.07	-0.08	0.13	-0.15	0.21	0.34	0.11	-0.2
Common Stock Shares Outstanding	0.38	0.26	0.46	0.52	0.59	0.27	-0.61	0.31	0.17	0.49	0.17	0.25		0.2	0.39	0.08	0.54	-0.06	0.46	-0.64	0.31	-0.47	0.3	-0.4	0.68	-0.6
Other Current Assets	0.32	-0.01	0.22	0.36	0.12	0.29	-0.19	0.37	-0.07	0.43	-0.07	0.39	0.2		0.34	0.19	-0.13	-0.08	0.42	0.07	0.39	-0.07	0.44	-0.36	0.17	-0.47
Other Stockholder Equity	0.1	0.16	0.61	0.18	0.68	-0.07	-0.28	0.15	0.53	0.15	0.53	-0.33	0.39	0.34		-0.05	0.19	-0.06	0.12	-0.15	-0.11	-0.41	-0.03	-0.97	0.43	-0.33
Total Liab	0.88	-0.08	0.4	0.7	0.19	-0.19	0.12	0.62	-0.03	0.79	-0.03	-0.04	0.08	0.19	-0.05		-0.06	0.65	0.81	-0.08	0.65	0.65	0.07	0.15	-0.22	0.15
Property Plant And Equipment Gross	0.01	0.6	0.33	0.06	0.53	0.54	-0.87	-0.1	0.15	0.11	0.15	0.04	0.54	-0.13	0.19	-0.06		-0.22	0.09	-0.88	0.31	-0.35	-0.24	-0.23	0.78	-0.51
Total Current Assets	0.64	-0.09	0.31	0.57	0.09	-0.38	0.36	0.27	0.12	0.34	0.12	0.06	-0.06	-0.08	-0.06	0.65	-0.22		0.35	0.0	0.04	0.39	-0.18	0.16	-0.39	0.53
Intangible Assets	0.94	0.01	0.51	0.91	0.35	0.04	-0.22	0.79	-0.01	1.0	-0.01	0.07	0.46	0.42	0.12	0.81	0.09	0.35		-0.21	0.73	0.19	0.41	-0.08	0.15	-0.38
Current Deferred Revenue	-0.18	-0.57	-0.42	-0.23	-0.55	-0.61	0.81	0.05	0.01	-0.22	0.01	-0.08	-0.64	0.07	-0.15	-0.08	-0.88	0.0	-0.21		-0.4	0.27	0.15	0.2	-0.71	0.45
Good Will	0.6	0.38	0.42	0.5	0.25	0.38	-0.44	0.49	-0.24	0.72	-0.24	0.13	0.31	0.39	-0.11	0.65	0.31	0.04	0.73	-0.4		0.29	0.41	0.09	0.28	-0.45
Non Current Liabilities Total	0.26	-0.41	-0.23	-0.02	-0.27	-0.23	0.58	0.23	-0.36	0.14	-0.36	-0.15	-0.47	-0.07	-0.41	0.65	-0.35	0.39	0.19	0.27	0.29		-0.18	0.47	-0.66	0.64
Short Term Debt	0.27	-0.08	0.19	0.37	0.15	-0.03	-0.06	0.55	-0.05	0.41	-0.05	0.21	0.3	0.44	-0.03	0.07	-0.24	-0.18	0.41	0.15	0.41	-0.18		0.0	0.06	-0.48
Non Currrent Assets Other	-0.03	-0.19	-0.57	-0.14	-0.7	-0.12	0.35	-0.15	-0.37	-0.11	-0.37	0.34	-0.4	-0.36	-0.97	0.15	-0.23	0.16	-0.08	0.2	0.09	0.47	0.0		-0.49	0.43
Common Stock Total Equity	0.01	0.59	0.56	0.16	0.58	0.52	-0.92	-0.06	0.27	0.19	0.27	0.11	0.68	0.17	0.43	-0.22	0.78	-0.39	0.15	-0.71	0.28	-0.66	0.06	-0.49		-0.77
Inventory	-0.14	-0.46	-0.37	-0.31	-0.41	-0.56	0.82	-0.22	-0.06	-0.41	-0.06	-0.2	-0.6	-0.47	-0.33	0.15	-0.51	0.53	-0.38	0.45	-0.45	0.64	-0.48	0.43	-0.77

Click cells to compare fundamentals

Mesoblast Account Relationship Matchups

Mesoblast fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	733.6M	744.7M	662.1M	669.4M	669.2M	583.1M
Other Current Liab	29.2M	18.7M	20.1M	5.4M	49.7M	52.2M
Total Current Liabilities	90.1M	94.3M	51.4M	42.0M	73.2M	40.1M
Total Stockholder Equity	549.3M	581.4M	497.0M	501.8M	480.4M	419.6M
Property Plant And Equipment Net	10.3M	12.1M	10.0M	6.5M	3.8M	3.6M
Net Debt	(30.0M)	(31.4M)	46.9M	45.6M	56.0M	58.8M
Retained Earnings	(548.8M)	(647.6M)	(738.9M)	(820.8M)	(908.8M)	(863.3M)
Accounts Payable	25.0M	19.6M	23.1M	20.1M	7.1M	6.7M
Cash	129.3M	136.9M	60.0M	70.9M	63.0M	67.3M
Non Current Assets Total	597.1M	596.5M	592.3M	587.8M	582.7M	466.6M
Cash And Short Term Investments	129.3M	136.9M	60.0M	70.9M	63.0M	67.3M
Net Receivables	1.6M	4.8M	4.4M	7.0M	21.0M	22.0M
Common Stock Shares Outstanding	55.8M	119.1M	129.8M	77.9M	98.7M	66.2M
Liabilities And Stockholders Equity	733.6M	744.7M	662.1M	669.4M	669.2M	583.1M
Other Current Assets	7.2M	6.5M	5.0M	2.9M	2.6M	3.8M
Other Stockholder Equity	1.1B	1.2B	1.2B	73.5M	84.5M	80.3M
Total Liab	184.3M	163.3M	165.1M	167.6M	188.8M	163.4M
Property Plant And Equipment Gross	10.3M	12.1M	28.3M	28.5M	24.1M	25.3M
Total Current Assets	136.5M	148.2M	69.8M	81.7M	86.5M	116.5M
Accumulated Other Comprehensive Income	46.6M	65.8M	70.7M	73.5M	78.3M	46.0M
Intangible Assets	447.1M	446.1M	444.2M	442.7M	441.3M	352.8M
Non Current Liabilities Total	94.1M	69.0M	113.7M	125.6M	115.6M	128.2M
Short Term Debt	36.0M	56.0M	8.2M	10.0M	16.5M	25.5M
Non Currrent Assets Other	(75.8M)	(78.4M)	(86.3M)	481K	2.1M	2.2M
Common Stock Total Equity	889.5M	910.4M	1.1B	1.2B	1.3B	939.2M
Inventory	(4.1M)	(1.6M)	(4.8M)	398K	358.2K	340.3K
Common Stock	1.1B	1.2B	1.2B	1.2B	1.3B	1.0B
Other Liab	30.8M	19.5M	15.0M	19.1M	17.2M	16.3M
Net Tangible Assets	(32.3M)	851K	(81.6M)	(75.3M)	(86.6M)	(91.0M)
Other Assets	3.3M	1.7M	1.9M	2.3M	2.1M	2.0M
Property Plant Equipment	10.3M	12.1M	10.0M	6.5M	7.5M	6.0M
Long Term Investments	1.9M	2.1M	1.8M	1.8M	1.0M	1.6M
Net Invested Capital	638.8M	675.6M	593.7M	610.6M	594.7M	659.7M
Net Working Capital	46.4M	54.0M	18.5M	39.7M	13.2M	12.6M
Short Long Term Debt Total	99.3M	105.5M	106.9M	116.5M	118.9M	108.1M
Long Term Debt	57.0M	41.0M	91.6M	102.8M	100.5M	81.7M
Short Long Term Debt	32.5M	53.2M	5.0M	6.0M	13.9M	21.0M

Pair Trading with Mesoblast

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mesoblast position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mesoblast will appreciate offsetting losses from the drop in the long position's value.

Moving together with Mesoblast Stock

0.83	ESPR	Esperion Therapeutics Buyout Trend	Pair Corr
0.77	EWTX	Edgewise Therapeutics	Pair Corr
0.62	BHC	Bausch Health Companies	Pair Corr

Moving against Mesoblast Stock

0.81	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.76	JNJ	Johnson Johnson Sell-off Trend	Pair Corr
0.76	TAK	Takeda Pharmaceutical	Pair Corr
0.72	HLN	Haleon plc	Pair Corr
0.7	RDY	Dr Reddys Laboratories	Pair Corr

The ability to find closely correlated positions to Mesoblast could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mesoblast when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mesoblast - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mesoblast to buy it.

The correlation of Mesoblast is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mesoblast moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mesoblast moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Mesoblast can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Mesoblast offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mesoblast's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mesoblast Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mesoblast Stock:

How To Invest In Mesoblast

Details

Is Mesoblast Stock a good investment?

Details

What is Mesoblast's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mesoblast. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.

You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mesoblast. If investors know Mesoblast will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mesoblast listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.05)

Revenue Per Share

0.06

Quarterly Revenue Growth

(0.41)

Return On Assets

(0.05)

Return On Equity

(0.18)

The market value of Mesoblast is measured differently than its book value, which is the value of Mesoblast that is recorded on the company's balance sheet. Investors also form their own opinion of Mesoblast's value that differs from its market value or its book value, called intrinsic value, which is Mesoblast's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mesoblast's market value can be influenced by many factors that don't directly affect Mesoblast's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Mesoblast's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mesoblast is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mesoblast's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Mesoblast Total Operating Expenses vs Selling And Marketing Expenses Analysis

Total Operating Expenses vs Selling And Marketing Expenses

Total Operating Expenses vs Selling And Marketing Expenses Correlation Analysis

Correlation Coefficient

Total Operating Expenses

Selling And Marketing Expenses

Mesoblast fundamental ratios Correlations

Mesoblast Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Mesoblast fundamental ratios Accounts

Pair Trading with Mesoblast

Moving together with Mesoblast Stock

Moving against Mesoblast Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Intangible Assets	+ 1.0	Non Current Assets Total
Total Stockholder Equity	+ 0.95	Total Assets
Non Current Assets Total	+ 0.94	Total Assets
Intangible Assets	+ 0.94	Total Assets
Non Current Assets Total	+ 0.92	Total Stockholder Equity

Non Currrent Assets Other	- 0.97	Other Stockholder Equity
Common Stock Total Equity	- 0.92	Retained Earnings
Current Deferred Revenue	- 0.88	Property Plant And Equipment Gross
Property Plant And Equipment Gross	- 0.87	Retained Earnings
Inventory	- 0.77	Common Stock Total Equity
Retained Earnings	- 0.72	Other Current Liab